pharma · Activated Phosphoinositide 3-Kinase Delta Syndrome · primary immunodeficiency
Pharming Technologies
Pharming Technologies B.V.
Pharming Technologies is a pharma organization headquartered in Leiden, NL. Primary therapeutic focus areas include Activated Phosphoinositide 3-Kinase Delta Syndrome, primary immunodeficiency, Common variable immunodefi
Leiden, NL HQ
6 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Leiden, NL
- Employees
- 6
- Programs
- 8
- Drugs
- 11
- Patents
- 0
KL1333 2025-104B
Phase 2 · other · Adult patients with primary mitochondrial disease
KL1333 2025-104B for Adult patients with primary mitochondrial disease is a Phase 2 program (other) at Pharming Technologies B.V. with 1 ClinicalTrials.gov record(s).
Internal code KL1333 2025-104B
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pharming Technologies B.V.
- Phase
- Phase 2
- Modality
- other
- Indication
- Adult patients with primary mitochondrial disease
- Status
- active
- Trials
- 1